Variability in St. John's wort formulations is an important consideration.
Kroll
D J
DJ
Shaw
H S
HS
Wall
M E
ME
Oberlies
N H
NH
D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D001643:Bridged Bicyclo Compounds; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects*; D003863:Depression / Q000188:drug therapy; D006801:Humans; D020902:Hypericum / Q000737:chemistry*; D006899:Mixed Function Oxygenases / Q000187:drug effects*; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D010696:Phloroglucinol / Q000031:analogs & derivatives; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use; D013729:Terpenes / Q000009:adverse effects*
D000900:Anti-Bacterial Agents; D001643:Bridged Bicyclo Compounds; D010936:Plant Extracts; D013729:Terpenes; D003577:Cytochrome P-450 Enzyme System; D010696:Phloroglucinol; D006899:Mixed Function Oxygenases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; C001654:hyperforin